AR075989A1 - Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria - Google Patents

Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria

Info

Publication number
AR075989A1
AR075989A1 ARP100101019A ARP100101019A AR075989A1 AR 075989 A1 AR075989 A1 AR 075989A1 AR P100101019 A ARP100101019 A AR P100101019A AR P100101019 A ARP100101019 A AR P100101019A AR 075989 A1 AR075989 A1 AR 075989A1
Authority
AR
Argentina
Prior art keywords
dkk
antibody
seq
dickkopf
engineering
Prior art date
Application number
ARP100101019A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR075989A1 publication Critical patent/AR075989A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP100101019A 2009-04-10 2010-03-29 Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria AR075989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10

Publications (1)

Publication Number Publication Date
AR075989A1 true AR075989A1 (es) 2011-05-11

Family

ID=42199718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101019A AR075989A1 (es) 2009-04-10 2010-03-29 Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria

Country Status (30)

Country Link
US (1) US8148498B2 (https=)
EP (3) EP2417158B9 (https=)
JP (1) JP5759977B2 (https=)
KR (3) KR20110124364A (https=)
CN (1) CN102388065B (https=)
AR (1) AR075989A1 (https=)
AU (1) AU2010234611B2 (https=)
BR (1) BRPI1014157B1 (https=)
CA (1) CA2758252C (https=)
CY (3) CY1119399T1 (https=)
DK (3) DK2930184T3 (https=)
EA (1) EA021401B1 (https=)
ES (3) ES2887176T3 (https=)
HR (3) HRP20171400T1 (https=)
HU (3) HUE055376T2 (https=)
IL (1) IL214845A (https=)
LT (3) LT2930184T (https=)
ME (2) ME02798B (https=)
MX (1) MX2011010707A (https=)
NZ (1) NZ595011A (https=)
PL (3) PL2930184T3 (https=)
PT (3) PT2930184T (https=)
RS (3) RS58612B1 (https=)
SG (1) SG175244A1 (https=)
SI (3) SI2930184T1 (https=)
TR (1) TR201907261T4 (https=)
TW (1) TWI546079B (https=)
UA (1) UA103916C2 (https=)
WO (1) WO2010117980A1 (https=)
ZA (1) ZA201107256B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120475A1 (es) 2009-05-12 2012-05-05 Pfizer Anticuerpos especificos para dkk-1
CN111961134B (zh) 2012-12-10 2024-04-05 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途
AU2016263030A1 (en) * 2015-05-18 2017-10-12 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
AU2019301160A1 (en) * 2018-07-11 2021-02-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CTLA-4
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
BR112022004851A2 (pt) * 2019-09-19 2022-08-23 Leap Therapeutics Inc Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en) 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
KR102494042B1 (ko) 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
IL304927A (en) * 2021-02-05 2023-10-01 Omeros Corp A biomarker for assessing the risk of developing acute COVID-19 and post-acute COVID-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
EP4471056A4 (en) * 2022-01-28 2026-02-18 Shanghai Junshi Biosciences Co Ltd Anti-DKK1 antibodies, pharmaceutical composition and associated uses
KR20250057775A (ko) 2022-07-12 2025-04-29 리프 테라퓨틱스 인코포레이티드 조합 요법
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU7137398A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
EP1636388A2 (en) 2003-06-06 2006-03-22 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
CN102421798A (zh) * 2009-05-07 2012-04-18 诺瓦提斯公司 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法

Also Published As

Publication number Publication date
SG175244A1 (en) 2011-12-29
EP3514173B8 (en) 2021-08-04
CY1119399T1 (el) 2018-02-14
CA2758252C (en) 2015-02-24
KR20140090273A (ko) 2014-07-16
HUE043904T2 (hu) 2019-09-30
PL2417158T3 (pl) 2017-12-29
PT2930184T (pt) 2019-06-17
RS62214B1 (sr) 2021-09-30
RS56505B1 (sr) 2018-02-28
CY1121637T1 (el) 2020-07-31
TR201907261T4 (tr) 2019-06-21
HUE034625T2 (en) 2018-02-28
EP2417158B9 (en) 2017-12-06
HUE055376T2 (hu) 2021-11-29
JP5759977B2 (ja) 2015-08-05
DK2930184T3 (da) 2019-05-13
ME03378B (me) 2020-01-20
KR20110124364A (ko) 2011-11-16
SI2930184T1 (sl) 2019-06-28
WO2010117980A1 (en) 2010-10-14
UA103916C2 (xx) 2013-12-10
LT3514173T (lt) 2021-09-10
HRP20190643T1 (hr) 2019-05-31
KR20140033523A (ko) 2014-03-18
LT2930184T (lt) 2019-05-10
KR101461362B1 (ko) 2014-11-13
CN102388065B (zh) 2014-09-03
CA2758252A1 (en) 2010-10-14
PT2417158T (pt) 2017-10-23
ES2644244T3 (es) 2017-11-28
EA201171237A1 (ru) 2012-04-30
HRP20171400T1 (hr) 2017-11-03
SI2417158T1 (sl) 2017-10-30
DK2417158T3 (en) 2017-10-16
BRPI1014157A2 (pt) 2020-09-29
TWI546079B (zh) 2016-08-21
EP3514173B1 (en) 2021-06-23
AU2010234611B2 (en) 2013-02-07
US8148498B2 (en) 2012-04-03
EP3514173A1 (en) 2019-07-24
RS58612B1 (sr) 2019-05-31
US20100260754A1 (en) 2010-10-14
DK3514173T3 (da) 2021-08-02
ZA201107256B (en) 2013-03-27
AU2010234611A1 (en) 2011-10-20
IL214845A (en) 2016-06-30
EA021401B1 (ru) 2015-06-30
ES2887176T3 (es) 2021-12-22
EP2417158A1 (en) 2012-02-15
CN102388065A (zh) 2012-03-21
ME02798B (me) 2018-01-20
EP2417158B1 (en) 2017-08-02
IL214845A0 (en) 2011-11-30
ES2728911T3 (es) 2019-10-29
HRP20211343T1 (hr) 2021-11-26
CY1124412T1 (el) 2022-07-22
MX2011010707A (es) 2012-02-28
PT3514173T (pt) 2021-08-16
PL2930184T3 (pl) 2019-10-31
DK2417158T4 (da) 2018-01-29
JP2012523417A (ja) 2012-10-04
NZ595011A (en) 2013-05-31
PL3514173T3 (pl) 2022-01-17
LT2417158T (lt) 2017-10-10
SI3514173T1 (sl) 2021-09-30
TW201100101A (en) 2011-01-01
EP2930184B1 (en) 2019-03-27
EP2930184A1 (en) 2015-10-14
BRPI1014157B1 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
AR075989A1 (es) Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
ZA202001564B (en) Anti- folate receptor alpha antibody conjugates and their uses
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CL2012001304A1 (es) Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
BR112014029966A2 (pt) proteínas de fator de crescimento de fibroblasto 21
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
BR112013009984A2 (pt) anticorpos para tratamento do hiv
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
MX349513B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
GT200900175A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
PE20141563A1 (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112016023979A2 (pt) métodos de melhora ou aceleração da recuperação física após cirurgia para fratura óssea
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
CL2007003191A1 (es) Compuestos derivados de pirimido-piridona, inhibidores de las proteina quinasas; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como artritis, sindrome de colon irritable, sindrome disneico agudo del adulto, epoc y para el
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
BRPI0517963A2 (pt) piridinureas antralinamidas como inibidores de receptores de cinases do fator de crescimento endotelial vascular
CO2020000260A2 (es) Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide

Legal Events

Date Code Title Description
FG Grant, registration